Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | hypothetical protein | 0.1035 | 0.2023 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1035 | 0.2023 | 0.5 |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Giardia lamblia | Hypothetical protein | 0.1035 | 0.2023 | 0.5 |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1724 | 0.6887 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.1754 | 0.7096 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.1724 | 0.6887 | 0.9706 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Onchocerca volvulus | 0.1754 | 0.7096 | 0.5 | |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1724 | 0.6887 | 0.9706 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1035 | 0.2023 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1724 | 0.6887 | 0.9706 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1724 | 0.6887 | 0.9604 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1035 | 0.2023 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1754 | 0.7096 | 1 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.2165 | 1 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.2165 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.